1. April 22, 2022

    PRAC April 2022 – No causal association found between the COVID-19 vaccines Comirnaty and Spikevax and autoimmune hepatitis

    During its April 2022 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) concluded that available evidence does not support a  causal link between COVID-19 vaccines Comirnaty and Spikevax and very rare cases of autoimmune hepatitis. 

    Source: FAMHP

    Read more

  2. April 15, 2022

    IFAPP Today newsletter - April 2022

    Source: IFAPP

    Please find here the link to the IFAPP TODAY newsletter of April 2022.

    Read more

  3. April 14, 2022

    Extension of the EU pilot project on simultaneous national scientific advice

    The Head of Medicines Agencies has approved the extension of the European pilot project for simultaneous national scientific advice at its 107th meeting in February 2022. The approval followed a positive evaluation of the first results of the project since its launch in February 2020.

    Source: FAMHP

    Read more

  4. April 1, 2022

    Accelerated scientific-technical advice on medicines against COVID-19

    Since the start of the COVID-19 health crisis, the FAMHP has given the highest priority to requests for national scientific-technical advice (STA) on medicines against COVID-19. The National Innovation Office and Scientific-Technical Advice Unit uses accelerated timelines for requests regarding medicines that prevent or cure COVID-19 infections. These timelines are crucial to support accelerated clinical research on new medicines against COVID-19.

    Source: FAMHP

    Read more

  5. March 28, 2022

    Coronavirus: monthly update of COVID-19 vaccines 24 March 2022

    Coronavirus: maandelijks overzicht bijwerkingen COVID-19-vaccins van 24 maart 2022

    Coronavirus : aperçu mensuel des effets indésirables des vaccins contre la COVID-19 du 24 mars 2022

    Source: FAMHP

    Read more

  6. March 28, 2022

    Genotoxic medicines and contraception: recommendations for all genotoxic active substances, regardless of therapeutic indication

    The European Medicines Agency's Safety Working Party clarifies its recommendations on genotoxic medicines and the duration of contraception to apply to any genotoxic active substance, regardless of its therapeutic indication. 

    Source: FAMHP

    Read more

  7. March 28, 2022

    Call for an important projects of common European interest in the health sector

    The FPS Economy published a call for interest from the Belgian federal and regional authorities for important projects of common European interest. The call is intended for economic operators who wish to take part in innovative projects at European level through various partnerships. The first documents should be sent by 30 March 2022 at the latest.

    Source: FAMHP

    Read more

  8. March 22, 2022

    Fight against antibiotic resistance: Amukin (amikacin) available again

    Het FAGG doet inspanningen om essentiële antibiotica op de markt te houden of te brengen. Een positief resultaat daarvan is dat Amukin na drie jaar afwezigheid op de markt nu opnieuw beschikbaar is. 

    Bron: FAGG

    L'AFMPS s'efforce de maintenir ou de mettre sur le marché des antibiotiques essentiels. Cet effort a notamment conduit à un résultat important : Amukin est à nouveau disponible après trois ans d'absence du marché.

    Source: AFMPS

    Read more

  9. March 22, 2022

    PRAC March 2022 – Update on COVID-19 vaccines and new safety information for dexmedetomidine

    During its March 2022 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has recommended a change to the product information for the COVID-19 vaccines of Janssen and Moderna. The Committee also discussed a direct healthcare professional communication containing important safety information for dexmedetomidine.

    Source: FAMHP

    Read more

  10. March 14, 2022

    Message from the IFAPP President

    An update on the collaboration between IFAPP and IFAPP Academy 

    Read more